India Approves Takeda's QDENGA – First Dengue Vaccine for Ages 4‑60

On Monday, the Drug Controller General of India (DCGI) officially approved QDENGA, a tetravalent live‑attenuated vaccine made by Takeda Biopharmaceuticals India. It’s the very first dengue vaccine the nation has ever sanctioned, and it can be given to children as young as four years old all the way up to adults aged sixty.

Why does this matter? Well, India’s dengue burden has exploded over the past twenty years – reported cases have risen more than eleven‑fold, and the country now shoulders roughly a third of the world’s dengue load. In 2025 alone, official figures topped 113,000, but epidemiologists warn the true number of infections may be in the tens of millions.

QDENGA is designed to protect against all four dengue virus serotypes. The good news is you don’t need any pre‑vaccination blood tests; the two‑dose schedule – a half‑milliliter shot given subcutaneously three months apart – works whether or not a person has previously faced dengue.

The vaccine already carries World Health Organization (WHO) recommendation for use in dengue‑endemic settings and has earned WHO pre‑qualification. That means it meets international standards for safety, quality and efficacy, and can be bought by agencies like UNICEF and PAHO for public‑sector programmes.

Since its rollout in 2022, QDENGA has found its way into 43 countries across Asia, Latin America and Europe, with more than 32 million doses administered through both public and private channels. The Indian approval rests on a massive global development effort – 19 Phase 1, 2 and 3 trials involving over 28,000 volunteers, including the landmark Phase III TIDES (DEN‑301) trial that enrolled more than 20,000 participants across eight nations.

Health experts say the timing couldn’t be better. Dengue still has no specific antiviral cure, and severe cases can quickly spiral into life‑threatening complications that demand intensive care. Having a vaccine that can be rolled out without the hassle of prior‑infection screening could be a game‑changer for India’s public‑health strategy.

As the country gears up to integrate QDENGA into its immunisation programmes, the hope is that a broader shield will curb the relentless rise of dengue and spare millions from its worst outcomes.